GE HealthCare’s PET imaging agent gains Alzheimer’s label expansion
The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.
25 June 2025
The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.